In a continued partnership with Takeda, Brandsymbol embarked on a groundbreaking project centered on an emerging asset for congenital thrombotic thrombocytopenic purpura (cTTP). This ultra-rare blood clotting disorder, caused by a deficiency in the ADAMTS13 enzyme, presented a significant unmet medical need, with acute events carrying a considerable mortality rate.

Takeda sought to redefine this landscape with a novel prophylactic and on-demand therapy for adult and pediatric cTTP patients, addressing both the acute and chronic manifestations of the condition. The treatment to be named was a recombinant ADAMTS13 (rADAMTS13) protein that emerged as the transformative solution that improved the efficiency of therapy and significantly boosted patients’ quality of life.

Brandsymbol collaborated closely with Takeda’s internal team to develop a fitting brand name for this transformative therapy. The result, ADZYNMA, combines “ADAMTS13” and “zen,” reflecting both the scientific nature of the treatment and the serene promise of improved quality of life for cTTP patients. This collaborative effort culminated in the FDA approval of ADZYNMA, marking a significant milestone in cTTP treatment.